P
ATOS icon

&Partners’s Atossa Therapeutics ATOS Stock Holding History

&Partners’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,867
Closed -$25.4K – 2401
2025
Q4 		$25.4K Buy
+2,867
New +$36.3K ﹤0.01% 2258

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

&Partners's ATOS Position: Q1 2026 in Review

&Partners sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 2,867 shares — an estimated $25.4K sold.

&Partners first reported a position in ATOS in Q4 2025 and held it in 1 quarter. The position peaked at $25.4K in Q4 2025. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • &Partners reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • &Partners sold 2,867 Atossa Therapeutics shares in Q1 2026, an estimated $25.4K.
  • &Partners first reported a position in Atossa Therapeutics in Q4 2025 and held it in 1 quarter.
  • &Partners's Atossa Therapeutics position peaked at $25.4K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.